100 related articles for article (PubMed ID: 23062910)
1. Aprepitant: a novel neurokinin-1 receptor/substance P antagonist as antipruritic therapy in cutaneous T-cell lymphoma.
Ladizinski B; Bazakas A; Olsen EA
J Am Acad Dermatol; 2012 Nov; 67(5):e198-9. PubMed ID: 23062910
[No Abstract] [Full Text] [Related]
2. Treatment of pruritus in early-stage hypopigmented mycosis fungoides with aprepitant.
Jiménez Gallo D; Albarrán Planelles C; Linares Barrios M; Fernández Anguita MJ; Márquez Enríquez J; Rodríguez Mateos ME
Dermatol Ther; 2014; 27(3):178-82. PubMed ID: 24517320
[TBL] [Abstract][Full Text] [Related]
3. Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature.
Song JS; Tawa M; Chau NG; Kupper TS; LeBoeuf NR
BMC Cancer; 2017 Mar; 17(1):200. PubMed ID: 28302100
[TBL] [Abstract][Full Text] [Related]
4. Antipruritic vs. Antitumour Action of Aprepitant: A Question of Dose.
Muñoz M; Parrilla J; Rosso M; Coveñas R
Acta Derm Venereol; 2019 May; 99(6):620-621. PubMed ID: 30734049
[No Abstract] [Full Text] [Related]
5. [Substance P receptor antagonists--a new antidepressive and anxiolytic mechanism?].
Lieb K; Fiebich BL; Berger M
Nervenarzt; 2000 Sep; 71(9):758-61. PubMed ID: 11042872
[TBL] [Abstract][Full Text] [Related]
6. Reward for persistence in substance P research.
Wahlestedt C
Science; 1998 Sep; 281(5383):1624-5. PubMed ID: 9767028
[No Abstract] [Full Text] [Related]
7. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder.
Keller M; Montgomery S; Ball W; Morrison M; Snavely D; Liu G; Hargreaves R; Hietala J; Lines C; Beebe K; Reines S
Biol Psychiatry; 2006 Feb; 59(3):216-23. PubMed ID: 16248986
[TBL] [Abstract][Full Text] [Related]
8. Substance P Antagonist Aprepitant Shows no Additive Effect Compared with Standardized Topical Treatment Alone in Patients with Atopic Dermatitis.
Lönndahl L; Holst M; Bradley M; Killasli H; Heilborn J; Hall MA; Theodorsson E; Holmberg J; Nordlind K
Acta Derm Venereol; 2018 Mar; 98(3):324-328. PubMed ID: 29182791
[TBL] [Abstract][Full Text] [Related]
9. [Role of aprepitant in the management of pruritus in a patient with cutaneous T-cell lymphoma].
Palacios Zabalza I; López de Torre Querejazu A; Santos Ibañez A
Farm Hosp; 2014 Apr; 38(2):145-7. PubMed ID: 24669900
[TBL] [Abstract][Full Text] [Related]
10. Aprepitant for antiemesis after laparoscopic gynaecological surgery: A randomised controlled trial.
Ham SY; Shim YH; Kim EH; Son MJ; Park WS; Lee JS
Eur J Anaesthesiol; 2016 Feb; 33(2):90-5. PubMed ID: 26694939
[TBL] [Abstract][Full Text] [Related]
11. NK-1 Antagonists and Itch.
Ständer S; Luger TA
Handb Exp Pharmacol; 2015; 226():237-55. PubMed ID: 25861784
[TBL] [Abstract][Full Text] [Related]
12. The NK1 receptor antagonist aprepitant attenuates NK1 agonist-induced scratching behaviour in the gerbil after intra-dermal, topical or oral administration.
Costantini VJ; Corsi M; Dünstl G; Bettelini L; Zonzini L; Gerrard P
Exp Dermatol; 2015 Apr; 24(4):312-4. PubMed ID: 25650546
[TBL] [Abstract][Full Text] [Related]
13. Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma.
Booken N; Heck M; Nicolay JP; Klemke CD; Goerdt S; Utikal J
Br J Dermatol; 2011 Mar; 164(3):665-7. PubMed ID: 21039410
[No Abstract] [Full Text] [Related]
14. Distinct mechanism for antidepressant activity by blockade of central substance P receptors.
Kramer MS; Cutler N; Feighner J; Shrivastava R; Carman J; Sramek JJ; Reines SA; Liu G; Snavely D; Wyatt-Knowles E; Hale JJ; Mills SG; MacCoss M; Swain CJ; Harrison T; Hill RG; Hefti F; Scolnick EM; Cascieri MA; Chicchi GG; Sadowski S; Williams AR; Hewson L; Smith D; Carlson EJ; Hargreaves RJ; Rupniak NM
Science; 1998 Sep; 281(5383):1640-5. PubMed ID: 9733503
[TBL] [Abstract][Full Text] [Related]
15. Topical non-peptide antagonists of sensory neurotransmitters substance P and CGRP do not modify patch test and prick test reactions: a vehicle-controlled, double-blind pilot study.
Wallengren J; Edvinsson L
Arch Dermatol Res; 2014 Jul; 306(5):505-9. PubMed ID: 24525842
[TBL] [Abstract][Full Text] [Related]
16. Antagonism of substance P and perception of breathlessness in patients with chronic obstructive pulmonary disease.
Mahler DA; Gifford AH; Gilani A; Waterman LA; Hilton J; Chang AS; Kupchak BR; Kraemer WJ
Respir Physiol Neurobiol; 2014 Jun; 196():1-7. PubMed ID: 24582719
[TBL] [Abstract][Full Text] [Related]
17. Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: A Randomized, Proof-of-Concept, Controlled Trial with Topical Aprepitant.
Ohanyan T; Schoepke N; Eirefelt S; Hoey G; Koopmann W; Hawro T; Maurer M; Metz M
Acta Derm Venereol; 2018 Jan; 98(1):26-31. PubMed ID: 28853492
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting.
Gan TJ; Apfel CC; Kovac A; Philip BK; Singla N; Minkowitz H; Habib AS; Knighton J; Carides AD; Zhang H; Horgan KJ; Evans JK; Lawson FC;
Anesth Analg; 2007 May; 104(5):1082-9, tables of contents. PubMed ID: 17456656
[TBL] [Abstract][Full Text] [Related]
19. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
20. Aprepitant (EMEND): the role of substance P in nausea and vomiting.
Prommer E
J Pain Palliat Care Pharmacother; 2005; 19(3):31-9. PubMed ID: 16219609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]